EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials

Aditya K Gupta iD, Tong Wang, Mary A Bamimore, Vincent Piguet, Antonella Tosti

Journal of Cosmetic Dermatology · 2023

DOI: 10.1111/jocd.15903 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Journal of Cosmetic Dermatology, 2023. Verfasst von Aditya K Gupta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Mediprobe Research Inc., London, Ontario, Canada. Hauptthemen laut MEDLINE: Alopecia Areata, Antibodies, Monoclonal, Humanized, Janus Kinase Inhibitors, Phosphodiesterase 4 Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Janus kinase (JAK) inhibitors, biologics, and phosphodiesterase‐4 (PDE‐4) inhibitors are recent therapies for alopecia areata (AA)—albeit, knowledge gaps exist for these agents' relative efficacy.

Objectives

We determined the relative efficacy and safety of monotherapy with the aforementioned agents in adults with AA.

Methods

The literature was systematically searched; we used data from randomized trials that investigated the agents' efficacy—as per Severity of Alopecia Tool (SALT) scores. Bayesian network meta‐analyses were used to determine relative efficacy and safety. Effect modification was determined using a generalized linear model on aggregate data; evidence quality was evaluated.

Results

Based on the surface under the cumulative ranking curve estimates obtained from multiple efficacy endpoints, regimens with the highest likelihood of achieving percent reduction in SALT scores, as well as a minimum 90%, 75% or 50% reduction in SALT scores are (in alphabetical order) baricitinib 4 mg once daily (QD), brepocitinib 60/30 mg QD, deuruxolitinib (CTP‐543) 12 mg twice daily (BID), ritlecitinib 200/50 mg QD, ruxolitinib 20 mg BID and tofacitinib 5 mg BID. In contrast, dupilumab subcutaneous injections administered weekly and apremilast 30 mg BID were less likely to be effective. Discontinuation due to any adverse event was the least likely with oral JAK inhibitors, and more likely with dupilumab and apremilast.

Conclusions

Our results support the conduct of high‐quality comparative trials to determine whether JAK inhibitors are more effective and safer than PDE4 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataAntibodies, Monoclonal, HumanizedJanus Kinase InhibitorsPhosphodiesterase 4 InhibitorsThalidomideAdultHumansAzetidinesBayes TheoremRandomized Controlled Trials as TopicSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

Janus kinase inhibitorsalopecia areatabiologicsnetwork meta-analysisseverity of alopecia tool

Substanzen

Antibodies, Monoclonal, HumanizedapremilastAzetidinesdupilumabJanus Kinase InhibitorsPhosphodiesterase 4 InhibitorsThalidomide

Autor:innen und Institutionen

  • Mediprobe Research Inc., London, Ontario, Canada.
  • Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada.
  • Division of Dermatology, Women's College Hospital, Toronto, Ontario, Canada.
  • Fredric Brandt Endowed Professor of Dermatology, University of Miami, Miami, Florida, USA.

ORCID-Profile: Aditya K Gupta

Zitieren

APA

Gupta, A. K., Wang, T., Bamimore, M. A., Piguet, V., & Tosti, A. (2023). The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.15903

Vancouver

Gupta AK, Wang T, Bamimore MA, Piguet V, Tosti A. The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials. Journal of Cosmetic Dermatology. 2023. doi:10.1111/jocd.15903

BibTeX
@article{Gupta2023,
  author = {Gupta, Aditya K and Wang, Tong and Bamimore, Mary A and Piguet, Vincent and Tosti, Antonella},
  title = {The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials},
  journal = {Journal of Cosmetic Dermatology},
  year = {2023},
  doi = {10.1111/jocd.15903}
}
Kostenlos starten →